BiologicalDrug
Tanezumab clinical trials
Also written PF-04383119 and RN624.
- studies test it
- 36
- open now
- 0
- in phase 3
- 18
- first study started
- 2006
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
36 studies that test it; most in 2009 (13)
| Year | Studies |
|---|---|
| 2006 | 2 |
| 2007 | 2 |
| 2008 | 6 |
| 2009 | 13 |
| 2010 | 6 |
| 2015 | 3 |
| 2016 | 3 |
| 2020 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 16
- Phase 3
- 18
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 35 · Other 1
Often tested with
Tested in the same studies.
Anti-Inflammatory Agents, Non-Steroidal (1)
Studies
Open first, then newest update. How each study uses tanezumab is read from its arms, and is right about nine times in ten.
Testing it · 36
- Phase 2 Study of Tanezumab in Subjects With Moderate to Severe Pain Due to SchwannomatosisActive, not recruitingPhase 2Massachusetts General HospitalNCT04163419Written as Tanezumab
- Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid TherapyCompletedPhase 3PfizerNCT02609828Written as Tanezumab
- A Study To Investigate Tanezumab In Patients With Interstitial Cystitis/ Painful Bladder SyndromeTerminatedPhase 2PfizerNCT00999518Written as Tanezumab
- RN624 In Adult Patients With Chronic Low Back PainCompletedPhase 2PfizerNCT00584870Written as PF-04383119 (RN624)
- A Study of Tanezumab in Adults With Chronic Low Back PainCompletedPhase 2PfizerNCT00876187Written as Tanezumab 20 mg IV
- Long-Term Analgesic Efficacy And Safety Of Tanezumab Alone Or In Combination With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Versus NSAIDs Alone In Patients With Osteoarthritis Of The Knee Or HipTerminatedPhase 3PfizerNCT00809354Written as tanezumab
- A Study Of Tanezumab as Add-On Therapy to Opioid Medication In Patients With Pain Due To Cancer That Has Spread To BoneCompletedPhase 2PfizerNCT00545129Written as Tanezumab 10 mg IV
- RN624 For Pain Of Post-Herpetic NeuralgiaCompletedPhase 2PfizerNCT00568321Written as RN624
- Tanezumab in Osteoarthritis of the Hip or Knee (2)CompletedPhase 3PfizerNCT00863304Written as tanezumab 10 mg
- Tanezumab In Osteoarthritis Of The Hip Or KneeTerminatedPhase 3PfizerNCT00985621Written as tanezumab 10 mg
- An Efficacy And Safety Study Of Tanezumab For The Treatment Of Pain Associated With Chronic Abacterial ProstatitisCompletedPhase 2PfizerNCT00826514Written as Tanezumab
- Tanezumab In Osteoarthritis Of The Knee (2)CompletedPhase 3PfizerNCT00830063Written as tanezumab 10 mg
- An Effectiveness and Safety Study of PF-04383119 for the Treatment of Pain in Interstitial CystitisCompletedPhase 2PfizerNCT00601484Written as PF-04383119
- A Long Term Study of the Safety of Tanezumab When Administered By Subcutaneous InjectionsTerminatedPhase 2PfizerNCT00994890Written as Tanezumab 2.5 mg
- Extension Study Of Tanezumab In OsteoarthritisTerminatedPhase 3PfizerNCT00809783Written as tanezumab
- Efficacy And Safety Study Of Tanezumab Subcutaneous Administration In Osteoarthritis - A Subcutaneous/Intravenous Bridging StudyTerminatedPhase 3PfizerNCT01089725Written as Tanezumab SC
- Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or KneeCompletedPhase 3PfizerNCT02697773Written as Tanezumab 2.5 mg
- A Clinical Study To Investigate The Effectiveness And Safety Of Tanezumab In Treating Pain Associated With EndometriosisTerminatedPhase 2PfizerNCT00784693Written as Tanezumab
- Long Term Safety Study of Tanezumab in Chronic Low Back PainTerminatedPhase 2PfizerNCT00924664Written as Tanezumab 20 mg
- Safety And Efficacy Of Tanezumab In Patients With Chronic PancreatitisTerminatedPhase 2PfizerNCT01146561Written as Tanezumab
Codes
What other systems call tanezumab · ClinicalTrials.gg INT005618
- MeSH (NLM) C549319tanezumabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) EQL0E9GCX1TANEZUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q3980782TanezumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C71522TanezumabOne source FDA
- DrugBank DB12335One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C549319 | tanezumab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | EQL0E9GCX1 | TANEZUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q3980782 | Tanezumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C71522 | Tanezumab | One source FDA |
| DrugBank | DB12335 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.